Group B streptococcal infection screening

Jump to navigation Jump to search

Group B Streptococcal Infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Group B Streptococcal Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Group B streptococcal infection screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Group B streptococcal infection screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Group B streptococcal infection screening

CDC on Group B streptococcal infection screening

Group B streptococcal infection screening in the news

Blogs on Group B streptococcal infection screening

Directions to Hospitals Treating Group B streptococcal infection

Risk calculators and risk factors for Group B streptococcal infection screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [3]

Overview

Screening

Indications

CDC's guidelines recommend universal culture-based screening for all pregnant women for vaginal and rectal GBS colonization (class A, level of evidence II) to determine which women should receive intrapartum GBS chemoprophylaxis. CDC recommended that women with unknown GBS colonization status at the time of delivery be managed according to the presence of intrapartum risk factors.

Timing

CDC's guidelines recommend screening for vaginal and rectal GBS colonization at 35-37 weeks' gestation.

Culture- Versus Risk-Based Screening

Early guidelines recommended the use of one of two approaches to identifying women who should receive intrapartum antibiotic prophylaxis: a risk-based approach or a culture-based screening approach.[1] A large population-based study conducted during 1998--1999 demonstrated the superiority of culture-based screening over the risk-based approach to prevention of early-onset GBS disease.[2] The study found that culture-based screening resulted in the identification of a greater proportion of women at risk for transmitting GBS to their newborns.

=Risk-Based Method

Providers using the risk-based method identified candidates for intrapartum chemoprophylaxis according to the presence of any of the following intrapartum risk factors:

  • Delivery at <37 weeks' gestation
  • Intrapartum temperature ≥100.4ºF (≥38.0ºC)
  • Rupture of membranes for ≥18 hours

=Culture-Based Method

Providers using the culture-based screening method screened all pregnant women between 35 and 37 week's gestation for:

  • Vaginal GBS colonization
  • Rectal GBS colonization

Specimen Collection and Processing for GBS Screening

References

  1. CDC. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR 1996;45(No. RR-7).[1]
  2. Schrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig AS; et al. (2002). "A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates". N Engl J Med. 347 (4): 233–9. doi:10.1056/NEJMoa020205. PMID 12140298.

Template:Bacterial diseases


Template:WikiDoc Sources